Literature DB >> 21105108

Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis.

María Úbeda1, Leticia Muñoz, María-José Borrero, David Díaz, Rubén Francés, Jorge Monserrat, Margaret Lario, Lourdes Lledó, José Such, Melchor Álvarez-Mon, Agustín Albillos.   

Abstract

UNLABELLED: Systemic activation of the inflammatory immune system contributes to the progression of cirrhosis with ascites. Immune cells become activated after interacting at the mesenteric lymph nodes (MLNs) with bacteria translocated from the gut, and thereafter reach the bloodstream through recirculation. It is unknown whether systemic activation of the immune system is present in pre-ascitic cirrhosis, in which gut bacterial translocation has not been described. The purpose of this study was to determine whether systemic activation of the immune system initiates in rats with compensated carbon tetrachloride (CCl(4))-induced cirrhosis, and if so to establish the activation site of immune cells. We studied the activation status of immune cells in peripheral blood, MLNs, and hepatic lymph nodes (HLNs). Systemic inflammation was present in rats with cirrhosis, as shown by expansion (P < 0.01) of circulating total and inflammatory monocytes and recently activated CD134(+) T helper (T(h)) cells. The same populations of cells were increased (P < 0.01) in MLNs and HLNs. Bacterial translocation was absent in rats with cirrhosis or control rats, but bacterial DNA fragments were present in the MLNs of 54% of rats with cirrhosis. The liver was the source of activated immune cells present in the blood, as shown by the direct correlation between activated T(h) cells in the blood and HLNs, but not in MLNs, and the normalization by gut decontamination with antibiotics of activated cells in MLNs, but not in the blood or HLNs.
CONCLUSION: In experimental cirrhosis, systemic activation of the immune system occurs before ascites development and is driven by recirculation of cells activated in HLNs. In addition, in compensated cirrhosis, bacterial DNA fragments reach the MLNs, where they elicit a local inflammatory response.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21105108     DOI: 10.1002/hep.23961

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.

Authors:  Yaron Ilan
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 3.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

Review 4.  Liver cirrhosis and immune dysfunction.

Authors:  Elda Hasa; Phillipp Hartmann; Bernd Schnabl
Journal:  Int Immunol       Date:  2022-09-06       Impact factor: 5.071

Review 5.  Risk factors and outcome of bacterial infections in cirrhosis.

Authors:  Tony Bruns; Henning W Zimmermann; Andreas Stallmach
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

6.  Plasma L-cystine/L-glutamate imbalance increases tumor necrosis factor-alpha from CD14+ circulating monocytes in patients with advanced cirrhosis.

Authors:  Eiji Kakazu; Yoshiyuki Ueno; Yasuteru Kondo; Jun Inoue; Masashi Ninomiya; Osamu Kimura; Yuta Wakui; Koji Fukushima; Keiichi Tamai; Tooru Shimosegawa
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

7.  Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection.

Authors:  Mercedes Márquez; Paula Romero-Cores; Monserrat Montes-Oca; Andrés Martín-Aspas; María-José Soto-Cárdenas; Francisca Guerrero; Clotilde Fernández-Gutiérrez; José-Antonio Girón-González
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

8.  Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis.

Authors:  Yaron Ilan; Ami Ben Ya'acov; Yehudit Shabbat; Svetlana Gingis-Velitski; Einat Almon; Yoseph Shaaltiel
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

9.  The Relationship between Renal Dysfunction and Abnormalities of the Immune System in Patients with Decompensated Cirrhosis.

Authors:  Eiji Kakazu; Yasuteru Kondo; Tooru Shimosegawa
Journal:  ISRN Gastroenterol       Date:  2012-12-26

10.  Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis.

Authors:  Pedro Zapater; Isabel Gómez-Hurtado; Gloria Peiró; José Manuel González-Navajas; Irma García; Paula Giménez; Alba Moratalla; José Such; Rubén Francés
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.